Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis
Copyright © 2021 Elsevier Inc. All rights reserved.
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 225(2021) vom: 01. Apr., Seite 108680 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2021
|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
| Schlagworte: | Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review Anticitrullinated peptide antibodies Biological disease-modifying antirheumatic drugs (bDMARDs) Cytokines Immune responses Rheumatoid arthritis Anti-Citrullinated Protein Antibodies mehr... |
| Zusammenfassung: | Copyright © 2021 Elsevier Inc. All rights reserved. Genetic, environmental, and epigenetic factors simultaneously or serially contribute to immune cells and resident joint tissue cell abnormalities, invariably leading to joint destruction. Understanding the immune cell dysfunction in earlier years has brought forward life-changing therapeutics to patients with rheumatoid arthritis (RA). Further advances in the understanding of the immune and joint tissue-resident cell signaling and metabolic defects should produce additional tools to treat people with RA and foretell those who will respond to each biological or small drug. This review presents the latest evidence on RA pathogenesis and outlines the prospects for achieving precision medicine |
|---|---|
| Beschreibung: | Date Completed 11.06.2021 Date Revised 11.06.2021 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2021.108680 |